前蛋白转化酶枯草杆菌蛋白酶/kexin 9型抑制剂：过去、现在和未来。
Sabatine, M.S. & Laufs, U. (2026). Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future.. Eur Heart J. https://doi.org/10.1093/eurheartj/ehag148
Sabatine MS, Laufs U. Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future.. Eur Heart J. 2026; doi: 10.1093/eurheartj/ehag148
Sabatine MS, Laufs U. Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future.[J]. Eur Heart J. 2026. DOI: 10.1093/eurheartj/ehag148.
@article{sabatine2026,
author = {Marc S Sabatine and Ulrich Laufs},
title = {Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future.},
journal = {Eur Heart J},
year = {2026},
doi = {10.1093/eurheartj/ehag148},
note = {PMID: 41841775},
}
TY - JOUR AU - Marc S Sabatine AU - Ulrich Laufs TI - Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future. T2 - Eur Heart J PY - 2026 DO - 10.1093/eurheartj/ehag148 AN - PMID:41841775 ER -
On the basis of seminal genetic discoveries, proprotein convertase subtilisin/kexin Type 9 (PCSK9) inhibitors were developed as a new class of LDL cholesterol-lowering drug, with a potency on par with and on top of high-intensity statins and an excellent safety profile. A series of large cardiovascular outcomes trials have now established the ability of monoclonal antibody PCSK9 inhibitors to reduce the risk of major adverse cardiovascular outcomes across a broad range of patients, including those with a prior major atherosclerotic cardiovascular disease (ASCVD) event, those with atherosclerosis but without a prior major ASCVD event, and those with diabetes. Moreover, these trials have shown the clinical benefit of lowering LDL cholesterol to ∼1 mmol/L (∼40 mg/dL) in such patients. New members of this class are being studied including oral inhibitors, RNA interference, and gene therapy.